CLINICAL_TRIALS
trial_result
· 2020-10-05
Clinical Trial Update: Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris [Phase 3]
Summary
Phase 3 bioequivalence study of clindamycin gel 1% for acne vulgaris completed; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Akorn, Inc. | Conditions: Acne Vulgaris | Phase 3 | Status: COMPLETED | Results posted: 2020-10-05